Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT07945496

Bioequivalence of Dapagliflozin and Metformin Extended-release Tablets Versus XIGDUO® XR in Healthy Adult Subjects

Conditions: Bioequivalence

Sex: All
Ages: 18 Years – N/A
Healthy volunteers: Yes
Phase: EARLY_PHASE1
Enrollment: 78
Sponsor: The Affiliated Hospital of Qingdao University

Location: The Affiliated Hospital of Qingdao University Qingdao Shandong

Summary

This study was conducted to compare a test formulation of dapagliflozin/metformin extended-release tablets (10 mg/1000 mg) with the reference product, XIGDUO XR, in healthy Chinese adults. The main purpose was to determine whether the two products deliver similar amounts of dapagliflozin and metformin into the bloodstream at a similar rate. The study included separate groups of participants who received the medications under fasting conditions or fed conditions. In each group, participants received both the test and reference products on separate occasions, with a washout period between treatments. Blood samples were collected at scheduled times to measure the concentrations of dapagliflozin and metformin. The safety and tolerability of both products were also assessed . The results were used to evaluate whether the test and reference products were bioequivalent under fasting and fed conditions.

Eligibility Criteria

Inclusion Criteria: 1. Volunteer to sign the informed consent form before the trial and fully understand the trial content, process, and possible adverse reactions; 2. Be able to complete the study according to the requirements of the trial protocol; 3. The subjects are willing to sign the informed consent form (female subjects from 14 days before signing the informed consent form) and have no plans for pregnancy, sperm donation, or egg donation within 3 months after the last administration, and are willing to take effective contraceptive measures (non-pharmacological contraception during the trial period); 4. Male and female subjects aged 18 years and above (including 18 years old); 5. Male subjects must weigh no less than 50kg, while female subjects must weigh no less than 45kg, with a BMI ranging from 19.0 to 27.0 kg/m2 (inclusive). Exclusion Criteria: 1. Individuals with a history of specific allergies (such as asthma) or current allergic diseases (such as urticaria, eczema, etc.), or individuals with an allergic constitution (such as those allergic to two or more drugs, foods like milk, or pollen), or individuals known to be allergic to the components of this medication or similar substances; 2. Participants with serious medical histories involving the heart, liver, kidneys, digestive tract, nervous system, endocrine system, respiratory system, and mental disorders, who are deemed unsuitable by the research doctor to participate; 3. Clinically significant abnormalities determined by clinicians, including physical examination, vital signs examination, electrocardiogram, or clinical laboratory examination, etc; 4. Individuals with a history of or current genital fungal infections, as well as those currently experiencing hypoglycemia, urinary tract infections, and hypotension; 5. Individuals with swallowing difficulties or any history of gastrointestinal diseases that affect drug absorption (such as gastrectomy or small bowel resection, atrophic gastritis, gastrointestinal obstruction, etc.); 6. Those who have difficulty with blood collection, or cannot tolerate venipuncture, or have a history of syncope from blood or acupuncture; 7. Female subjects who are currently in the gestation period, lactation period, or have positive pregnancy test results; 8. Individuals with positive results for any one or more of hepatitis B surface antigen, hepatitis C antibody, Human Immunodeficiency Virus(HIV) antibody, or syphilis antibody; 9. Those who have a history of drug abuse within the past five years, or have used drugs within the past three months prior to screening, or have tested positive in urine drug screening; 10. Individuals who have consumed an average of more than 14 units of alcohol per week within the previous 3 months (1 unit = 360 mL of beer or 45 mL of strong liquor with an alcohol content of 40% or 150 mL of wine), or who do not agree to abstain from alcohol consumption from 48 hours before the start of each dosing period until the end of blood sample collection for that period, or who have tested positive in an alcohol breath test; 11. Screen out those who have smoked an average of more than 5 cigarettes per day within the previous 3 months or who do not agree to stop using any tobacco products during their stay; 12. Screen for individuals who have undergone surgical procedures within the previous 3 months or plan to undergo surgery during the study period; 13. Those who have donated blood or experienced significant blood loss (\>400mL, excluding physiological blood loss in women) within 3 months prior to the first dose of medication, or those who have donated 2 therapeutic doses of platelets (1 therapeutic dose = 12U of platelets) within 1 month; 14. Participants who have taken part in any drug clinical trial within 3 months prior to their first medication intake; 15. Subjects who have taken carbonic anhydrase inhibitors, organic cation transporter 2 (OCT2)/multidrug and toxin extrusion (MATE) inhibitors, and drugs affecting blood glucose control within 30 days prior to the first dose; 16. Those who have taken any prescription drugs within 14 days before the first dose; 17. Those who have taken any non-prescription drugs, Chinese herbal medicines, or health supplements within 7 days prior to the first dose of medication; 18. Those who have consumed special diets (such as grapefruit and products containing grapefruit ingredients) or engaged in strenuous exercise within 48 hours before taking the medication, or those who have other factors that affect drug absorption, distribution, metabolism, and excretion; 19. Those who have consumed any foods rich in xanthine-containing substances (such as coffee, tea, chocolate, cocoa, milk tea, etc.) within 48 hours prior to taking the medication; 20. Those who have special dietary requirements and cannot comply with the diet provided by the center and the corresponding regulations; 21. Those who developed acute diseases during the pre-screening phase of the study or before the administration of study medication; 22. Subjects deemed unsuitable for participation by other researchers.

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07945496). StuddyBuddy aggregates publicly available trial information.